Analyst firms · Morgan Stanley · CRL

Morgan Stanley CRL price target and rating history

Charles River Laboratories International Inc. (CRL) · Health Care

Morgan Stanley rates Charles River Laboratories International Inc. (CRL) Overweight with a $220 price target, as of its latest action on Jun 17, 2026. It has published 4 rating actions on CRL since November 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a CRL price target in the last 12 months, the median target is $220. Morgan Stanley's target matches it.

Current rating
Overweight
Price target
$220
Median target, all firms
$220
Actions on CRL
4

Morgan Stanley price target on CRL

$465$343$22020222023202420252026
Morgan Stanley price target on CRL, each point a stated target, November 2021 to June 2026.

Every Morgan Stanley rating on CRL

How other firms rate CRL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$357Sep 30, 2026
CLSAHold$219Jul 20, 2026
Morgan StanleyOverweight$220Jun 17, 2026
RBC Capital MarketsOutperform$215Apr 14, 2026
BofA SecuritiesBuy$225Dec 15, 2025
Argus ResearchBuyNov 17, 2025

Questions about Morgan Stanley and CRL

What is Morgan Stanley's price target for CRL?
Morgan Stanley's latest stated price target for Charles River Laboratories International Inc. (CRL) is $220, from its action on Jun 17, 2026.
What is Morgan Stanley's rating on CRL?
Morgan Stanley rates CRL Overweight, a bullish rating, as of Jun 17, 2026.
When did Morgan Stanley last change its view on CRL?
On Jun 17, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $220.
How does Morgan Stanley's CRL target compare with other analysts?
Across 5 firms with a CRL price target in the last 12 months, the median target is $220. Morgan Stanley's target matches it.

More CRL rating histories

All Morgan Stanley ratingsCRL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.